Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)

Summary

Participants will be randomized (1:1) to one of two sequences of a vaginal ring (VR) containing 25mg of dapivirine to be inserted monthly for 24 weeks and 200 mg FTC/300 mg TDF oral tablets taken daily for 24 weeks. After completing the randomized sequence of two study product use periods, participants will then select between the two study products to use in the final 24 weeks of the trial. Participants will be able to choose either or neither study product every 4 weeks during the third product use period.

Timeline

Start

2017-11

Primary completion

2018-12

Completion

2020-12-30

Outcome

Outcome not reported

Stopped: “Study was transferred to partner who will conduct under its own IND”

Publications

• Ngure K, Browne EN, Reddy K, Friedland BA, van der Straten A, Palanee-Phillips T, Nakalega R, Gati B, Kalule HN, Siziba B, Soto-Torres L, Nair G, Garcia M, Celum C, Roberts ST. Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial. AIDS Behav. 2024 Sep;28(9):2990-3000. doi: 10.1007/s10461-024-04382-3. Epub 2024 Jun 9.

Drugs

Indications